Why Novo Nordisk stock hit the market on Monday

Pursuing large-scale acquisition of controlling shareholders novo nordisk‘S (NGO 4.01%) The U.S.-listed stock rose 4% on Monday. As a result of this transaction, Novo Nordisk will acquire from its shareholders (Novo Holdings) the three filling sites currently operated by the target. Novo Nordisk’s stock price surge S&P 500 The index fell 0.3% during the session.

Parent company acquires Catalent in $16.5 billion deal

On Monday morning, Novo Holdings said it had signed an agreement to acquire the healthcare contract manufacturer. catalyst (CTLT 9.74%). The all-cash transaction was priced at $63.50 per share, representing a nearly 17% premium over Catalent’s closing price last Friday. This brings the company’s value to $16.5 billion. This transaction is expected to close by the end of this year.

Catalent operates more than 50 manufacturing facilities worldwide. Novo Holdings plans to sell three fill closure facilities to Novo Nordisk. Two are in Europe (Italy and Belgium, to be exact) and the third is in Bloomington, Indiana.

Novo Nordisk has particularly stood out in the United States due to the soaring popularity of its Wegovy obesity treatment. In the fourth quarter, Wegovy’s revenue nearly quadrupled.

A press release from Novo Nordisk announcing the three upcoming acquisitions wrote that this “will provide future selectivity and flexibility to Novo Nordisk’s existing supply network while allowing us to expand our manufacturing capacity at scale and speed.”

Expand charging capacity

All three sites already work with Novo Nordisk, so the transition to new ownership should be rapid. The company wrote that the three companies should begin expanding their charging capacity in 2026, but did not provide an estimate of that impact.